• 1
    International Diabetes Federation and International Society of Nephrology. Diabetes and Kidney Disease: Time to Act. Brussels: International Diabetes Federation and International Society of Nephrology, 2003.
  • 2
    Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:7827.
  • 3
    King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:141431.
  • 4
    Yoon K, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:16818.
  • 5
    Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: GanD, ed. Diabetes Atlas, 3rd edn. Brussels: International Diabetes Federation, 2006;15109.
  • 6
    Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic kidney disease. In: EkoéJ et al., ed. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley & Sons, 2008;499518.
  • 7
    National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007;23954.
  • 8
    McDonaldS, ExcellL, LivingstonB, eds. ANZDATA Registry Report 2008, Appendix II. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2008;197.
  • 9
    Yamagata K, Iseki K, Nitta K et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008;12:18.
  • 10
    Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 2002;13:S3740.
  • 11
    Adler A, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:22532.
  • 12
    Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:18329.
  • 13
    Parving H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69:205763.
  • 14
    Ninomiya T, Perkovic V, De Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:181321.
  • 15
    Dunstan D, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:82934.
  • 16
    White S, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008;188:2048.
  • 17
    Whaley-Connell A, Sowers JR, McCullough PA et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53(4 Suppl 4):S1121.
  • 18
    Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008;4:23.
  • 19
    Holman R, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:157789.
  • 20
    Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008;25(Suppl 2):259.
  • 21
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:58091.
  • 22
    Patel A; ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:82940.
  • 23
    ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:256072.
  • 24
    Zoungas S, De Galan BE, Ninomiya T et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009;32:206874.
  • 25
    Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:194151.
  • 26
    Parving H, Lehnert H, Brøchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:8708.
  • 27
    Lewis E, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001;345:85160.
  • 28
    Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009;18:10711.